Koskinas KC, et al. - This study analyzed data from randomized trials comparing clinical impact of more-intensive vs. less-intensive low-density lipoprotein cholesterol (LDL-C) lowering by means of statins and currently recommended non-statin medications in secondary prevention. Findings demonstrated that across a broad spectrum of on-treatment levels in secondary prevention, reduction of the major vascular event (MVE) was proportional to the magnitude of LDL-C lowering. In this very high-risk population, a significant reduction of cardiovascular morbidity was observed in association with statin intensification and add-on treatment with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors or ezetimibe.